미국의 동물 암 진단 시장 규모, 점유율, 동향 분석 보고서 : 동물 유형별, 검사 유형별, 암 유형별, 최종 용도별, 국가별, 부문 예측(2025-2030년)

U.S. Veterinary Oncology Diagnostics Market Growth & Trends:

The U.S. veterinary oncology diagnostics market size is expected to reach USD 1.60 billion by 2030, registering a CAGR of 8.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by growing animal population and ownership rates, increased expenditure on animals, an increasing focus on preventative animal healthcare, and growing partnerships among key players to expand product offerings. For instance, in February 2025, Torigen Pharmaceuticals and Proscia partnered to leverage AI-enabled digital pathology for faster, more accurate cancer diagnoses in pets. This enables quicker, personalized immunotherapy treatments, enhancing survival rates for dogs with metastatic hemangiosarcoma. Torigen's AI-powered diagnostics significantly enhance the accuracy and speed of cancer detection. By delivering results within 3-5 days, it reduces diagnostic turnaround time, allowing veterinarians to begin targeted treatments sooner. This innovation is expected to boost market growth by driving demand for digital pathology solutions in veterinary oncology.

Additionally, advances in veterinary cancer diagnostic testing, and rising R&D investment in animal health diagnostics to launch innovative products are fueling market growth. For instance, in December 2024, Pet Preferred Diagnostics introduced a groundbreaking early cancer diagnostic test for dogs and cats that detects 11 specific onconeural antibodies linked to 21 types of tumors and 14 neurological diseases. This highly sensitive serological test can identify malignancy, often before clinical signs appear, enabling early treatment. It is the only test available in veterinary medicine that differentiates various tumors and neurological conditions, offering a non-invasive, affordable, and quick solution with a 24-hour turnaround.

The rising prevalence of cancer in pets is a key driver of the U.S. veterinary oncology diagnostics market, with 1 in 4 dogs and 1 in 5 cats diagnosed with cancer annually. Increasing pet ownership and humanization trends have boosted demand for advanced diagnostics as pet owners seek early detection and personalized treatments. Technological advancements, such as liquid biopsy tests (e.g., OncoK9 by PetDx) and AI-powered digital pathology (e.g., Torigen and Proscia partnership), are enhancing diagnostic accuracy and efficiency. Additionally, the growing availability of affordable, at-home cancer screening tests (e.g., Oncotect) is making early diagnosis more accessible, further propelling market growth.

U.S. Veterinary Oncology Diagnostics Market Report Highlights:

• Based on test type, the biopsy segment dominated the market with a share of 28.75% in 2024. However, the genome testing segment is expected to grow at the fastest CAGR of 9.62% during the forecast period due to technological advancements in veterinary cancer diagnostic test kits.
• Based of animal type, the canine segment attributed to the largest revenue share in 2024 due to the increase in the dog cancer population and the availability of a huge number of products for canine cancer diagnosis. The feline segment is projected to grow at the fastest rate from 2025 to 2030, owing to the rising population of cats worldwide and the apparent rise in the number of associated diseases.
• Based on cancer type, the skin cancers segment accounted for the highest revenue share in 2024 and is expected to grow at the fastest CAGR of 8.71% owing to the rising prevalence of squamous cell carcinoma and skin tumors in cats and dogs.
• Based on end use, the veterinary hospitals and clinics segment held the highest revenue share of the market in 2024 owing to the increasing demand for diagnostics and readily accessible advanced veterinary cancer diagnostic technologies in hospitals. This segment is estimated to grow at the fastest CAGR in the coming years.
• Advances in innovative liquid biopsy and advanced multi-cancer diagnostic technology have led to the development of more accurate, user-friendly, and cost-effective veterinary oncology diagnostic test kits. Such advancements are expected to drive market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
• 1.4. Information/Data Analysis
• 1.5. Market Formulation & Visualization
• 1.6. Data Validation & Publishing
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis
  • 1.7.2. Global Market: CAGR Calculation
• 1.8. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Oncology Diagnostics Market Variable Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market
  • 3.1.2. Ancillary Market
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing prevalence of cancer in pets
    • 3.2.1.2. Increasing R&D in veterinary oncolgy diagnostics
    • 3.2.1.3. Growing focus on animal safety
    • 3.2.1.4. Growing uptake of pet insurance
    • 3.2.1.5. Technological advancements in early pet cancer diagnosis
    • 3.2.1.6. Increase in pet population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of veterinary oncology diagnostics
    • 3.2.2.2. Lack of awareness in developing countries
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. U.S. Veterinary Oncology Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitution
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental Landscape
  • 3.3.3. Regulatory Framework
  • 3.3.4. Estimated Animal Population, by Key Species, 2018 - 2024
  • 3.3.5. COVID-19 Impact Analysis

Chapter 4. U.S. Veterinary Oncology Diagnostics Market: Animal Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Veterinary Oncology Diagnostics Market Animal Type Movement Analysis
• 4.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Animal Type, 2018 - 2030 (USD Million)
  • 4.3.1. Canine
    • 4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.3.2. Feline
    • 4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Veterinary Oncology Diagnostics Market: Test Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Veterinary Oncology Diagnostics Market Test Type Movement Analysis
• 5.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Test Type 2018 - 2030 (USD Million)
  • 5.3.1. Blood Tests
    • 5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.2. Biopsy
    • 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Genome testing
    • 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.4. Endoscopy
    • 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.5. Urinalysis
    • 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.6. Imaging
    • 5.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Veterinary Oncology Diagnostics Market: Cancer Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Veterinary Oncology Diagnostics Market Cancer Type Movement Analysis
• 6.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By Cancer Type, 2018 - 2030 (USD Million)
  • 6.3.1. Lymphoma
    • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Sarcomas
    • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mammary Gland Tumors
    • 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.4. Skin Cancers
    • 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.5. Others
    • 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Veterinary Oncology Diagnostics Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Veterinary Oncology Diagnostics Market End-Use Movement Analysis
• 7.3. U.S. Veterinary Oncology Diagnostics Market Size & Trend Analysis, By End-Use 2018 - 2030 (USD Million)
  • 7.3.1. Reference Laboratories
    • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Veterinary hospitals and clinics
    • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Participants Overview
• 8.3. Financial Performance
• 8.4. Product Benchmarking
• 8.5. Market Position Analysis, 2024 (Heat Map Analysis)
• 8.6. Strategy Mapping
  • 8.6.1. Mergers and Acquisitions
  • 8.6.2. Launch
  • 8.6.3. Partnerships & Collaborations
  • 8.6.4. Expansion
  • 8.6.5. Others
• 8.7. Company Profiles
  • 8.7.1. Zoetis
    • 8.7.1.1. Participant's overview
    • 8.7.1.2. Financial performance
    • 8.7.1.3. Product Benchmarking
    • 8.7.1.4. Strategic initiatives
  • 8.7.2. Antech Diagnostics, Inc. (Mars Inc.)
    • 8.7.2.1. Participant's overview
    • 8.7.2.2. Financial performance
    • 8.7.2.3. Product Benchmarking
    • 8.7.2.4. Strategic initiatives
  • 8.7.3. IDEXX Laboratories, Inc.
    • 8.7.3.1. Participant's overview
    • 8.7.3.2. Financial performance
    • 8.7.3.3. Product Benchmarking
    • 8.7.3.4. Strategic initiatives
  • 8.7.4. Neogen Corporation
    • 8.7.4.1. Participant's overview
    • 8.7.4.2. Financial performance
    • 8.7.4.3. Product Benchmarking
    • 8.7.4.4. Strategic initiatives
  • 8.7.5. Gold Standard Diagnostics (Eurofins Technologies)
    • 8.7.5.1. Participant's overview
    • 8.7.5.2. Financial performance
    • 8.7.5.3. Product Benchmarking
    • 8.7.5.4. Strategic initiatives
  • 8.7.6. Embark Veterinary, Inc.
    • 8.7.6.1. Participant's overview
    • 8.7.6.2. Financial performance
    • 8.7.6.3. Product Benchmarking
    • 8.7.6.4. Strategic initiatives
  • 8.7.7. VolitionRx Limited
    • 8.7.7.1. Participant's overview
    • 8.7.7.2. Financial performance
    • 8.7.7.3. Product Benchmarking
    • 8.7.7.4. Strategic initiatives
  • 8.7.8. CANCAN DIAGNOSTICS
    • 8.7.8.1. Participant's overview
    • 8.7.8.2. Financial performance
    • 8.7.8.3. Product Benchmarking
    • 8.7.8.4. Strategic initiatives
  • 8.7.9. Oncotect
    • 8.7.9.1. Participant's overview
    • 8.7.9.2. Financial performance
    • 8.7.9.3. Product Benchmarking
    • 8.7.9.4. Strategic initiatives
  • 8.7.10. PetDx
    • 8.7.10.1. Participant's overview
    • 8.7.10.2. Financial performance
    • 8.7.10.3. Product Benchmarking
    • 8.7.10.4. Strategic initiatives